ProQR Therapeutics N.V. (PRQR)Healthcare | Biotechnology | Leiden, Netherlands | NasdaqCM
1.78 USD
-0.07
(-3.523%) ⇩
(April 21, 2026, 12:08 p.m.
EDT)
Short-term: ★★★★☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:29 p.m. EDT
AI-driven drug discovery pipeline is igniting speculative zeal, evidenced by the 'strong_buy' analyst consensus and aggressive 2026 clinic targets. Technically, the stock rebounds above the 60-day SMA, confirming short-term momentum. However, this is a binary play on upcoming clinical data; the lack of dividend yield and negative fundamentals mean this remains a high-volatility venture rather than a wealth-building income vehicle. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.075478 |
| AutoETS | 0.076787 |
| AutoARIMA | 0.076788 |
| AutoTheta | 0.133903 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.66 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.513 |
| Excess Kurtosis | -0.63 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 32.333 |
| Revenue per Share | 0.155 |
| Market Cap | 187,015,888 |
| Forward P/E | -3.78 |
| Beta | 0.09 |
| Profit Margins | -258.05% |
| Website | https://www.proqr.com |
As of April 18, 2026, 11:29 p.m. EDT: Options market is highly skewed bullish, with net volume concentrated almost exclusively in the 2.5 strikes (Weakly OTM). The 05/15 and 07/17 expirations show significant new call volume at the 2.5 strike, creating new flow anchors. In contrast, put activity is negligible (only 1 net volume contract in July), indicating a lack of fear and weak downside protection. Bid-ask spreads and Volume/Ask imbalances suggest speculative positioning for a rapid move above the 2.0 PSW resistance zone.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.36296296 |
| Address1 | Zernikedreef 9 |
| All Time High | 27.6 |
| All Time Low | 0.53 |
| Ask | 2.27 |
| Ask Size | 2 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 741,940 |
| Average Daily Volume3 Month | 450,286 |
| Average Volume | 450,286 |
| Average Volume10Days | 741,940 |
| Beta | 0.093 |
| Bid | 1.33 |
| Bid Size | 2 |
| Book Value | 0.54827976 |
| City | Leiden |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Netherlands |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.775 |
| Current Ratio | 3.086 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.89 |
| Day Low | 1.7701 |
| Debt To Equity | 32.333 |
| Display Name | ProQR Therapeutics |
| Earnings Timestamp | 1,773,318,600 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | -42,544,000 |
| Ebitda Margins | -2.60256 |
| Enterprise To Ebitda | -2.76 |
| Enterprise To Revenue | 7.183 |
| Enterprise Value | 117,415,360 |
| Eps Forward | -0.47 |
| Eps Trailing Twelve Months | -0.47 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.6536 |
| Fifty Day Average Change | 0.1214 |
| Fifty Day Average Change Percent | 0.07341558 |
| Fifty Two Week Change Percent | 36.296295 |
| Fifty Two Week High | 3.1 |
| Fifty Two Week High Change | -1.3249999 |
| Fifty Two Week High Change Percent | -0.42741933 |
| Fifty Two Week Low | 1.31 |
| Fifty Two Week Low Change | 0.46500003 |
| Fifty Two Week Low Change Percent | 0.35496187 |
| Fifty Two Week Range | 1.31 - 3.1 |
| Financial Currency | EUR |
| First Trade Date Milliseconds | 1,411,047,000,000 |
| Float Shares | 64,346,109 |
| Forward Eps | -0.47 |
| Forward P E | -3.7765956 |
| Free Cashflow | -32,042,376 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 186 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 16,347,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.17665 |
| Held Percent Institutions | 0.50794 |
| Implied Shares Outstanding | 105,361,064 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands. |
| Long Name | ProQR Therapeutics N.V. |
| Market | us_market |
| Market Cap | 187,015,888 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_224193775 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -42,184,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 192,810,747 |
| Number Of Analyst Opinions | 8 |
| Open | 1.83 |
| Operating Cashflow | -52,791,000 |
| Operating Margins | -1.92897 |
| Payout Ratio | 0.0 |
| Phone | 31 88 166 7000 |
| Previous Close | 1.84 |
| Price Hint | 4 |
| Price To Book | 3.2373984 |
| Price To Sales Trailing12 Months | 11.44038 |
| Profit Margins | -2.5805302 |
| Quick Ratio | 3.005 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.125 |
| Region | US |
| Regular Market Change | -0.06500006 |
| Regular Market Change Percent | -3.5232294 |
| Regular Market Day High | 1.89 |
| Regular Market Day Low | 1.7701 |
| Regular Market Day Range | 1.7701 - 1.89 |
| Regular Market Open | 1.83 |
| Regular Market Previous Close | 1.84 |
| Regular Market Price | 1.775 |
| Regular Market Time | 1,776,787,710 |
| Regular Market Volume | 232,571 |
| Return On Assets | -0.19346 |
| Return On Equity | -0.61165 |
| Revenue Growth | 0.061 |
| Revenue Per Share | 0.155 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 105,361,064 |
| Shares Percent Shares Out | 0.015800001 |
| Shares Short | 1,667,465 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,704,877 |
| Short Name | ProQR Therapeutics N.V. |
| Short Percent Of Float | 0.0233 |
| Short Ratio | 4.24 |
| Source Interval | 15 |
| Symbol | PRQR |
| Target High Price | 14.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 8.875 |
| Target Median Price | 8.5 |
| Total Cash | 92,413,000 |
| Total Cash Per Share | 0.877 |
| Total Debt | 15,964,000 |
| Total Revenue | 16,347,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.47 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.047 |
| Two Hundred Day Average Change | -0.27199996 |
| Two Hundred Day Average Change Percent | -0.13287736 |
| Type Disp | Equity |
| Volume | 232,571 |
| Website | https://www.proqr.com |
| Zip | 2,333 CK |